![](\"https:\/\/mms.businesswire.com\/media\/20260521633963\/en\/1736351\/4\/Natera_floret_Logo.jpg\"){kind=logo}
<\/a><\/a>\nAt its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional space in a second building within the same complex, designed to support continued business growth and operational scale.<\/p>
\nNatera\u2019s facility is expected to have the largest sequencing capacity in the world. This new space will help enable the company to meet the increasing demand for its testing solutions, particularly in oncology where year-over-year volumes increased by more than 54% in the first quarter of 2026. Natera's SignateraTM<\/sup> test has become a foundational tool in precision oncology and is used today by more than 50% of U.S. oncologists. Last week, SignateraTM<\/sup> CDx became the first FDA-approved companion diagnostic in molecular residual disease testing.<\/p> \nNatera is also continuing to support substantial investments in research and development, with participation in hundreds of clinical trials and research collaborations across its business. These efforts are helping generate the evidence needed to expand the use of personalized diagnostics and bring new innovations to patients worldwide.<\/p> \n\u201cWith this expansion, we will have an even greater opportunity to serve patients,\u201d said John Fesko, president, chief business officer of Natera. \u201cBy expanding our lab space and sequencing capacity, we are investing in the infrastructure needed to serve more patients, support additional clinicians, and continue advancing personalized medicine at scale.\u201d<\/p> \nNatera expects to create up to 400 new jobs across professional, laboratory, and operational roles through this expansion.<\/p> \nAbout Natera<\/b><\/p> \nNatera\u2122 is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com<\/a>.<\/p> \nForward-Looking Statements<\/b><\/p> \nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in \"Risk Factors\" in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com\/investors<\/a> and www.sec.gov<\/a>.<\/p> \nInvestor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com<\/a> Company to open second facility and new lab space to accommodate rapid growthAUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operation…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9501","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9501"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9501\/revisions"}],"predecessor-version":[{"id":9502,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9501\/revisions\/9502"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}